Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Stewart

Showing results (181-190 of 208) with videos related to

Pageof 21
Sort By:
Mayo Clinic Proceedings|August 12, 2006
Mayo clinic consensus statement for the use of bisphosphonates in multiple myelomaMartha Q Lacy, Angela Dispenzieri, Morie A Gertz, et al.
Mayo Clinic Proceedings|August 8, 2015
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus StatementAngela Dispenzieri, Francis Buadi, Shaji K Kumar, et al.
Cancer Cell|August 19, 2007
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myelomaJonathan J Keats, Rafael Fonseca, Marta Chesi, et al.
Plos One|October 17, 2012
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencingWinnie S Liang, David W Craig, John Carpten, et al.
Mayo Clinic Proceedings|March 15, 2017
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted TherapyDavid Dingli, Sikander Ailawadhi, P Leif Bergsagel, et al.
Nature Medicine|November 15, 2016
IAP antagonists induce anti-tumor immunity in multiple myelomaMarta Chesi, Noweeda N Mirza, Victoria M Garbitt, et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|March 12, 2014
Implementing individualized medicine into the medical practiceKonstantinos N Lazaridis, Tammy M McAllister, Dusica Babovic-Vuksanovic, et al.
Blood|July 8, 2017
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myelomaJonas Paludo, Joseph R Mikhael, Betsy R LaPlant, et al.
The New England Journal of Medicine|December 9, 2014
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaA Keith Stewart, S Vincent Rajkumar, Meletios A Dimopoulos, et al.
JAMA Oncology|October 30, 2020
Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer SyndromeN Jewel Samadder, Douglas Riegert-Johnson, Lisa Boardman, et al.
Pageof 21

Showing results (181-190 of 208) with videos related to

Sort By:
Pageof 21
Mayo Clinic Proceedings|August 12, 2006
Mayo clinic consensus statement for the use of bisphosphonates in multiple myelomaMartha Q Lacy, Angela Dispenzieri, Morie A Gertz, et al.
Mayo Clinic Proceedings|August 8, 2015
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus StatementAngela Dispenzieri, Francis Buadi, Shaji K Kumar, et al.
Cancer Cell|August 19, 2007
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myelomaJonathan J Keats, Rafael Fonseca, Marta Chesi, et al.
Plos One|October 17, 2012
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencingWinnie S Liang, David W Craig, John Carpten, et al.
Mayo Clinic Proceedings|March 15, 2017
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted TherapyDavid Dingli, Sikander Ailawadhi, P Leif Bergsagel, et al.
Nature Medicine|November 15, 2016
IAP antagonists induce anti-tumor immunity in multiple myelomaMarta Chesi, Noweeda N Mirza, Victoria M Garbitt, et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|March 12, 2014
Implementing individualized medicine into the medical practiceKonstantinos N Lazaridis, Tammy M McAllister, Dusica Babovic-Vuksanovic, et al.
Blood|July 8, 2017
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myelomaJonas Paludo, Joseph R Mikhael, Betsy R LaPlant, et al.
The New England Journal of Medicine|December 9, 2014
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaA Keith Stewart, S Vincent Rajkumar, Meletios A Dimopoulos, et al.
JAMA Oncology|October 30, 2020
Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer SyndromeN Jewel Samadder, Douglas Riegert-Johnson, Lisa Boardman, et al.
Pageof 21